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A B S T R A C T
Background
Pneumonia is the leading cause of mortality in children under five years of age. Treatment of pneumonia requires an effective antibiotic
used in adequate doses for an appropriate duration. Recommended duration of treatment ranges between 7 and 14 days, but this is
not based on any empirical evidence. Shorter duration of therapy, if found to be effective, could be particularly important in resource-
poor settings where there is a high risk of death, poor access to medicines and health care and limited budgets for medicines.
Objectives
To evaluate the efficacy of short-course versus long-course therapy with the same antibiotic for non-severe community-acquired
pneumonia (CAP) in children aged 2 to 59 months.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 3) which contains the
Cochrane Acute Respiratory Infections Group’s Specialised Register and the Database of Abstracts of Reviews of Effects, MEDLINE
(OVID) (January 1966 to August Week 4, 2010), EMBASE (Embase.com) (1974 to August 2010) and LILACS (1982 to August
2010).
Selection criteria
All randomised controlled trials (RCTs) evaluating the efficacy of short-course versus long-course therapy using the same antibiotic for
non-severe CAP in children.
Data collection and analysis
Two review authors independently assessed trial quality and extracted the data.
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Main results
Four studies (6177 children) were included. Analysis of three days versus five days of treatment with the same antibiotic for non-
severe CAP in children showed non-significant differences in rates of clinical cure at the end of treatment (risk ratio (RR) 0.99; 95%
confidence interval (CI) 0.97 to 1.01), treatment failure at the end of treatment (RR 1.07; 95% CI 0.92 to 1.25), and relapse rate after
seven days of clinical cure (RR 1.09; 95% CI 0.84 to 1.42), and we found no heterogeneity in the results. Subgroup analysis evaluating
the impact of different antibiotics showed non-significant differences for these outcomes with different durations of therapy.
Authors’ conclusions
The evidence of this review suggests that a short course (three days) of antibiotic therapy is as effective as a longer treatment (five days)
for non-severe CAP in children under five years of age. However, there is a need for more well-designed RCTs to support our review
findings.
P L A I N L A N G U A G E S U M M A R Y
Comparing different durations of the same antibiotic therapy for non-severe community-acquired pneumonia in children under
five years of age
Pneumonia is a major cause of mortality in children under five years of age. Treatment of pneumonia requires the use of an effective
antibiotic in adequate doses for an appropriate duration. In most cases, treatment ranges between 7 and 14 days, but this is not based
on any empirical evidence. Shorter duration of therapy, if found to be effective, would not only be beneficial in resource-poor settings
but also result in improved adherence to therapy and reduced resistance to antibiotics and adverse effects. This review of four studies
involving 6177 children found that a short course (three days) of antibiotic therapy is equally as effective as a longer treatment (five
days) for non-severe pneumonia. We also found that different durations of either amoxicillin or cotrimoxazole give similar results in
terms of clinical cure, failure of the treatment and rate of relapse.
B A C K G R O U N D
Description of the condition
Pneumonia is an infection of the lungs (Gaston 2002). Pneumo-
nia can be caused by organisms such as bacteria and viruses. In
children, the organisms which cause pneumonia vary with the age
of the child (McIntosh 2002; UNICEF 2006). Group B strepto-
coccus and gram-negative enteric bacteria are the most common
pathogens in neonates (from birth to 20 days after birth), whereas
in infants aged between three weeks and three months Streptococ-
cus pneumoniae (S. pneumoniae) is the most common pathogen.
In infants older than four months and in preschool-aged children
viruses are a frequent cause and S. pneumoniae is themost common
bacterial pathogen (Ostapchuk 2004; Sinianiotis 2005). Staphylo-
coccus aureus (S. aureus) and Haemophilus influenzae (H. influen-
zae), including non-typable, are also common causes of childhood
pneumonia in low-income countries (McIntosh 2002; UNICEF
2006).
Acute lower respiratory tract infections (LRTIs) are among the
leading causes of mortality in children under five years of age
(Bryce 2005; Rudan 2008); they account for nearly two million
deaths each year with most of the deaths occurring in low-income
countries. Pneumonia is the largest killer, accounting for 19%of all
child deaths in low-income countries (Bryce 2005; Rudan 2008).
Interventions that affect mortality due to pneumonia are therefore
of great importance in an effort to improve child survival.
Description of the intervention
Definitions of pneumonia vary widely. Some require evidence of
the presence of infiltrates on a chest radiograph, whereas others
require certain respiratory signs or symptoms (McIntosh 2002).
The World Health Organization (WHO) has defined pneumonia
solely on the basis of clinical findings obtained by visual inspec-
tion and setting respiratory rate cut-offs (WHO 1981). According
to the WHO guideline, a respiratory rate of > 50 per minute in
infants aged two to 11 months and a respiratory rate of > 40 per
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minute in children younger than 12 to 59 months with no lower
chest in-drawing, suggests non-severe pneumonia; while a respira-
tory rate of > 50 per minute in infants aged two to 11 months and
a respiratory rate of > 40 per minute in children younger than 12
to 59 months plus lower chest in-drawing indicates severe pneu-
monia. Indicators for severe pneumonia plus convulsions, abnor-
mal sleep and difficulty in waking up, stridor in a calm child and
inability to drink, indicate very severe pneumonia. To reduce the
number of people dying from pneumonia, the WHO developed
standard guidelines for the management of acute respiratory tract
infections (ARTIs) (WHO 1990). These guidelines were devel-
oped using evidence from studies on aetiology, clinical aspects and
susceptibility (WHO 1991). As S. pneumoniae and H. influenzae
are the most common causes of childhood pneumonia in low-in-
come countries, theWHO recommends using oral cotrimoxazole
or amoxicillin as first-line drugs for treatment of non-severe CAP
at first-level health facilities (WHO 1990; WHO 1991). These
guidelines have effectively reduced death from pneumonia in low-
income countries (Sazawal 2003).
How the intervention might work
Treatment of CAP requires the use of an effective antibiotic given
in adequate doses and for an appropriate duration. Recommenda-
tions for antibiotic therapy for CAP are based, in general, on aetio-
logical diagnosis (Prober 2000). Identification of the causative or-
ganism in routine clinical care is rare and is not usually attempted.
Because of these diagnostic problems empirical antibiotic therapy
is the commonly accepted practice worldwide (McIntosh 2002).
In most cases the duration of treatment ranges between 7 and 14
days, but this is not based on any empirical evidence. Rather this
treatment duration seems to be the result of initial treatment stud-
ies of tonsillo-pharyngitis, which was treated for 10 to 14 days
(Pichichero 2000).
Why it is important to do this review
Optimum duration of therapy for CAP is especially important
in resource-poor settings where there is a high risk of death,
poor access to medicines and health care, and limited budgets for
medicines (Campbell 1995). Important aspects of a shorter course
of antibiotic therapy, if found to be effective and without an in-
crease in morbidity and mortality, include improved adherence to
therapy, reduced antimicrobial resistance and lowered cost.
O B J E C T I V E S
To evaluate the efficacy of short-course versus long-course therapy
with the same antibiotic for non-severe CAP in children aged 2 to
59 months.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) evaluating the efficacy of
short-course versus long-course therapy using the same antibiotic
for non-severe CAP in children. We considered studies using a
standard WHO algorithm for ARTIs (WHO 1991), which de-
fines non-severe CAP as cough or difficult and fast breathing (res-
piratory rate of 50 breaths per minute or more for children aged 2
months to 11 months, or respiratory rate of 40 breaths per minute
or more for children aged 12 months to 59 months). We also in-
cluded trials published in languages other than English after trans-
lation. We excluded non-randomised (quasi-randomised) trials.
Types of participants
We included children aged 2 months to 59 months with non-
severe CAP.We excluded studies including children with severe or
very severe CAP (defined on the basis of chest in-drawing, inability
to drink, convulsions, abnormal sleepiness or difficulty waking),
any chronic illness, or those who had received antibiotics in the
past 48 hours.
Types of interventions
Short-course versus long-course therapy using the same antibiotic
for non-severe CAP in children. We performed a comparison of
different durations of antibiotic therapies (durations between three
to seven days).
Types of outcome measures
Primary outcomes
Clinical cure rate, defined as return of respiratory rate to the normal
age-specific range.
Secondary outcomes
1. Treatment failure: defined as development of chest in-
drawing, convulsions, drowsiness, or inability to drink at any
time; respiratory rate above the age-specific cut-off on
completion of treatment; or oxygen saturation, measured by
pulse oximetry, of less than 90% after completion of the
treatment; loss to follow up or withdrawal from the study.
2. Relapse rate: defined as development of any sign of CAP
within seven days after fast breathing had returned to normal.
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3. Additional interventions used.
4. Mortality at one month.
Search methods for identification of studies
Electronic searches
For this update we searched the Cochrane Central Register of
Controlled Trials (CENTRAL) (The Cochrane Library 2010, Is-
sue 3) which contains the Cochrane Acute Respiratory Infections
Group’s Specialised Register and the Database of Abstracts of Re-
views of Effects, MEDLINE (OVID) (January 1966 to August
Week 4, 2010), EMBASE (Embase.com) (1974 to August 2010)
and LILACS (1982 to August 2010). See Appendix 1 for details
of previous searches.
We used the following search terms to search MEDLINE and
CENTRAL. We combined the MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision) (Lefebvre 2008). The search strategy
also incorporated the search strategy devised by Boluyt 2008 to
identify child studies. We adapted the terms to search EMBASE
(Appendix 2) and LILACS (Appendix 3).
MEDLINE (OVID)
1 exp Pneumonia/
2 (pneumon* or CAP).mp.
3 lower respiratory tract infection*.mp.
4 lower respiratory infection*.mp.
5 LRTI.mp.
6 or/1-5
7 exp Anti-Bacterial Agents/
8 antibiotic*.mp.
9 exp Anti-Infective Agents/
10 exp Amoxicillin/
11 exp Penicillins/
12 exp Ampicillin/
13 exp Trimethoprim-Sulfamethoxazole Combination/
14 exp Macrolides/
15 exp Erythromycin/
16 exp Azithromycin/
17 exp Clarithromycin/
18 (penicillin* or amoxicillin or ampicillin or cotrimoxa-
zole or macrolide* or erythromycin or azithromycin or clar-
ithromycin).mp.
19 or/7-18
20 6 and 19 )
21 exp Infant/ )
22 (infant* or infancy or newborn* or baby* or babies or neonat*
or preterm* or prematur*).tw.
23 exp Child/
24 (child* or schoolchild* or school age* or preschool* or kid or
kids or toddler*).tw.
25 Adolescent/
26 (adoles* or teen* or boy* or girl*).tw.
27 Minors/
28 Puberty/
29 (minor* or pubert* or pubescen*).tw.
30 exp Pediatrics/
31 (pediatric* or pediatric*).tw.
32 exp Schools/
33 (nursery school* or kindergar* or primary school* or secondary
school* or elementary school* or high school* or highschool*).tw.
34 or/21-33
35 20 and 34 (12429)
Searching other resources
We limited searches to human studies andwe imposed no language
or publication restrictions.We also searched the related conference
proceedings for relevant abstracts. We contacted organisations and
researchers in the field and pharmaceutical companies for infor-
mation on unpublished and ongoing trials. We also checked the
reference lists of all trials identified by the above methods.
Data collection and analysis
Selection of studies
Two review authors (BAH, ZSL) independently assessed the eli-
gibility of the trials. We selected studies as being potentially rele-
vant by screening the titles and abstracts, if available. We retrieved
and reviewed the full text of the article if we could not ascertain
the relevance of studies by screening the title and the abstract.
We retrieved full texts of all potentially relevant articles and in-
dependently assessed the eligibility by filling out eligibility forms
designed in accordance with the specified inclusion criteria. We
resolved disagreements by discussion and a consensus was reached.
Data extraction and management
We carried out data extraction using a data extraction form which
was designed and pilot tested by the review authors. The form
extracted information regarding:
1. study setting (for example, country, type of population and
socioeconomic status);
2. description of antibiotic used (including type of drug, dose,
duration and frequency);
3. sample size;
4. length of follow up;
5. randomisation procedure; and
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6. outcomes as listed above.
We extracted the total number of participants for each group for
dichotomous outcomes and the number of participants experienc-
ing an event. There were no continuous outcomes in our review.
Assessment of risk of bias in included studies
Two review authors (BAH, ZSL) independently assessed the ’Risk
of bias’ for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2009).
A third review author (ZAB) resolved any disagreements by dis-
cussion.
(1) Sequence generation (checking for possible selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups. We assessed the
method as:
• adequate (any truly random process, for example, random
number table, computer random number generator);
• inadequate (any non-random process, for example, odd or
even date of birth, hospital or clinic record number); or
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence in sufficient detail and determine whether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment. We assessed the
methods as:
• adequate (for example, telephone or central randomisation,
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation, unsealed or non-
opaque envelopes, alternation, date of birth); or
• unclear.
(3) Blinding (checking for possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. Studies were judged at low risk
of bias if theywere blinded, or if we judged that the lack of blinding
could not have affected the results. Blindingwas assessed separately
for different outcomes or classes of outcomes. We assessed the
methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel; and
• adequate, inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook. We assessed methods as:
• adequate;
• inadequate; or
• unclear.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• adequate (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• inadequate (where not all the study’s pre-specified outcomes
have been reported; one or more reported primary outcomes
were not pre-specified; outcomes of interest are reported
incompletely and so cannot be used; study fails to include results
of a key outcome that would have been expected to have been
reported); or
• unclear.
(6) Other sources of bias
We described for each included study any important concerns we
have about other possible sources of bias. We assessed whether
each study was free of other problems that could put it at risk of
bias:
• yes;
• no; or
• unclear.
(7) Overall ’Risk of bias’
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2009). With reference
to (1) to (6) above, we assessed the likely magnitude and direction
of the bias and whether we consider it is likely to impact on the
findings. We also explored the impact of the level of bias through
undertaking sensitivity analyses.
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Measures of treatment effect
We extracted the total number of participants for each group and
the number of participants experiencing an event for dichotomous
outcomes. We used the risk ratio (RR) and 95% confidence inter-
vals (CIs).
Dealing with missing data
We noted levels of attrition for included studies. For all outcomes,
analysis was carried out, as far as possible, on an intention-to-
treat (ITT) basis, i.e. we attempted to include all participants
randomised to each group in the analyses.
Assessment of heterogeneity
We measured heterogeneity among the trials by calculating the I²
statistic, Chi² test P value and by visual inspection of the forest
plots. If the I² statistic exceeded 30%, Chi² test P value was less
than 0.1, and visual inspection of the forest plots was indicative of
heterogeneity in effect size, then heterogeneity would have been
considered to be substantial. We did not find any heterogeneity,
therefore subgroup analyses based on differences in dosage, fre-
quency, bacterial or viral aetiology, baseline infant mortality, half-
lives of antibiotic used and differences in the techniques for diag-
nosing CAP were not sought. However, we attempted to look for
the use of different antibiotics.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2008). We used fixed-effect inverse variance meta-
analysis for combining data because trials were examining the same
intervention, and the trials’ populations and methods were judged
sufficiently similar.
Subgroup analysis and investigation of heterogeneity
We pre-specified the following subgroup analysis to investigate
heterogeneity.
1. Dosage and frequency of antibiotics used.
2. High baseline infant mortality.
3. Bacterial or viral aetiology.
4. Differences in the half-lives of the antibiotics used.
5. Characteristics of the study population.
6. Differences in the technique for diagnosing CAP.
Sensitivity analysis
We undertook sensitivity analysis to study the effect of a short
course versus a long course of antibiotic therapy on clinical cure,
treatment failure and relapse rates of non-severe CAP by exclud-
ing the Kartasasmita 2002 study, for which we did not have in-
formation regarding allocation concealment, blinding and loss to
follow up. However, the overall effect estimates and CIs were not
sensitive to this change.
R E S U L T S
Description of studies
Results of the search
In this update a total of 296 records were retrieved during the
search.
Included studies
We identified only four studies (Agarwal 2004;Kartasasmita 2002;
Lupison 1999; MASCOT 2002) as potentially eligible for inclu-
sion in our review. The trial by the ISCAP study group (Agarwal
2004) was conducted in India. The trial by the MASCOT pneu-
monia study group (MASCOT 2002) was conducted in Pakistan.
The trial by Lupison (Lupison 1999) was conducted in Pasay City,
Philippines. The trial by the Cotrimoxazole Study Group was
conducted in Indonesia and Bangladesh (Kartasasmita 2002). All
studies were double-blind and placebo-controlled with individual
randomisation of the treatment groups. Participants included chil-
dren aged 2 to 59 months diagnosed with non-severe CAP which
was defined as respiratory rate of more than or equal to 50 breaths
per minute for children aged 2 to 11 months, or more than or
equal to 40 breaths per minute for children aged 12 to 59 months.
Children with severe CAP, any chronic illness and those who had
received antibiotics in the previous two days were excluded from
the Agarwal 2004 and MASCOT 2002 studies. In Lupison 1999
children were excluded if they presented with ongoing antibiotic
treatment for the present illness, chest in-drawing, cyanosis, in-
ability to drink, lethargy, convulsion, severe malnutrition, severe
complicating illness, chronic disease, chronic otitis media with
acute exacerbation and allergy to cotrimoxazole. There was no
significant difference in the baseline characteristics of the study
groups (Agarwal 2004; Lupison 1999; MASCOT 2002). We can-
not comment on the exclusion criteria used for the participants in
the Kartasasmita 2002 study as it is still in its abstract form.
The Agarwal 2004 and MASCOT 2002 studies compared three
days versus five days of treatment with oral amoxicillin, given
three times daily. In Agarwal 2004 participants received scored
dispersible tablets of amoxicillin 125 mg dissolved in 5 ml of water
containing an approximate effective dose per kg body weight of 31
to 54 mg/day for the first three days. The dose in the MASCOT
2002 was 15 mg/kg every eight hours for the initial three days.
This was followed by either active medicine or a placebo for the
next two days. The Kartasasmita 2002 study evaluated three days
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of oral cotrimoxazole against five days of therapy. In Lupison 1999
children older than 12 months were given cotrimoxazole 80 mg
BID (twice a day) and children 2 to 12 months old were given
cotrimoxazole 40 mg BID.
Please refer to theCharacteristics of included studies table formore
details.
Excluded studies
We excluded six studies (El Moussaoui 2006; Ficnar 1997; Harris
1998; Leophonte 2002; Peltola 2001; Siegal 1999) as they did not
satisfy the inclusion criteria of the review. The study by Harris
(Harris 1998) included children aged 6months to 16 years, Peltola
(Peltola 2001) included children aged 3 months to 15 years, and
Ficnar (Ficnar 1997) included children of 6 months to 12 years.
These studies did not report their outcomes separately for children
younger than five years of age. Also Ficnar (Ficnar 1997) was not
a RCT. On the other hand, three studies (El Moussaoui 2006;
Leophonte 2002; Siegal 1999) only included adult populations.
Please refer to theCharacteristics of excluded studies table formore
details.
Risk of bias in included studies
Figure 1 and Figure 2 summarise the risk of bias in the included
studies. Methodological details for each trial can be found in the
Characteristics of included studies table.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation
The Agarwal 2004 and MASCOT 2002 studies were of adequate
methodological quality. Participants were individually randomised
to the treatment groups with adequate allocation concealment in
both studies. In Lupison 1999 numbers were computer-generated
and were only known to the programmer. Block randomisation
with uneven block sizes was used. Participants were also individu-
ally randomised in the Kartasasmita 2002 study but information
regarding allocation concealment was not available.
Blinding
Two studies (Agarwal 2004; MASCOT 2002) showed adequate
blinding of the participants, caregivers and outcome assessors.
In Lupison 1999 caregivers were blinded to the treatment and
placebo assignment. Block randomisation with uneven block sizes
was used. Information regarding blinding was not available in
Kartasasmita 2002.
Incomplete outcome data
Loss to follow up was around 5% at first follow up in three studies
(Agarwal 2004; Lupison 1999; MASCOT 2002). However insuf-
ficient information in Kartasasmita 2002 did not allow us to make
any judgement.
Selective reporting
Agarwal 2004, MASCOT 2002 and Lupison 1999 appeared to
be free from selective reporting, while insufficient information
from Kartasasmita 2002 did not permit any conclusion regarding
selective reporting.
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Other potential sources of bias
Agarwal 2004, MASCOT 2002 and Lupison 1999 appeared
to be free from other bias, while insufficient information from
Kartasasmita 2002 did not permit us to draw any conclusions from
it.
Effects of interventions
The analysis includes data of 6177 children from four included
studies.
Primary outcome measure
Analysis of three days versus five days of treatment with the same
antibiotic for non-severe CAP in children showed non-significant
differences in clinical cure at first follow up at the end of treatment
(RR 0.99; 95% CI 0.97 to 1.01, three studies (fixed-effect, n =
5763)) and there was no heterogeneity (Chi² test, P value 0.68; I²
statistic = 0%) (Analysis 1.1; Figure 3). When data were disaggre-
gated on the basis of antibiotic used, which included amoxicillin
and cotrimoxazole, summary estimates and theCIs remained non-
significant.
Figure 3. Forest plot of comparison: 1 3 days versus 5 days treatment with the same antibiotic, outcome:
1.1 Clinical cure.
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Secondary outcome measures
When three days of treatment was compared against five days
of treatment with the same antibiotic, non-significant differences
were found for rates of treatment failure at the end of treatment
(RR 1.07; 95% CI 0.92 to 1.25, three studies (fixed-effect, n =
5763)) and there was no heterogeneity (Chi² test, P value 0.63;
I² statistic = 0%) (Analysis 1.2; Figure 4) and relapse rate after
seven days of clinical cure (RR 1.09; 95% CI 0.84 to 1.42, four
studies (fixed-effect, n = 5469)) and there was no heterogeneity
(Chi² test, P value 0.97; I² statistic = 0%) (Analysis 1.3; Figure 5).
When a subgroup analysis was undertaken on the basis of whether
amoxicillin or cotrimoxazole was used, non-significant differences
were found for the outcomes of treatment failure and relapse rate
with the different durations of the therapy used.
Figure 4. Forest plot of comparison: 1 3 days versus 5 days treatment with the same antibiotic, outcome:
1.2 Treatment failure.
10Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59
months (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 5. Forest plot of comparison: 1 3 days versus 5 days treatment with the same antibiotic, outcome:
1.3 Relapse rate.
Outcomes of mortality at one month and additional interventions
used could not be evaluated in this review due to non-availability
of data from the included studies. There was no significant het-
erogeneity among the trials assessed on the basis of visual inspec-
tion of forest plots and the I² statistic, hence the following a priori
subgroup analyses were not undertaken.
D I S C U S S I O N
Summary of main results
Pneumonia in children under five years of age accounts for the
highest number of deaths in low-income countries. This review
addressed an important aspect of treatment, which is the opti-
mal duration of antibiotic therapy. Short durations of antibiotic
therapy have been found to be effective in upper respiratory tract
infections (Pichichero 2000). Evidence for efficacy in acute lower
respiratory tract infections (LRTIs) is limited. Effective shortened
durations of antibiotic therapy for community-acquired pneumo-
nia (CAP) would be especially beneficial for low-income countries
and resource-poor settings as it would lead to a reduction in the
overall cost of treatment, improved compliance and tolerance of
treatment and reduced antimicrobial resistance. We found only
four studies evaluating the efficacy of short-course versus long-
course therapy using the same antibiotic for non-severe CAP in
children under five years of age, and these were all from low-in-
come countries such as Pakistan, India, Bangladesh and the Philip-
pines. All the included studies evaluated the same durations of
short and long courses of therapy, which were three days versus five
days. Analysis showed that treatment with an oral antibiotic for ei-
ther three days or five days was equally efficacious in treating non-
severe CAP in children. Three days of treatment failed to show
significant differences in clinical cure, treatment failure or relapse
rates compared to five days of treatment with the same antibiotic.
There was no significant heterogeneity among the included stud-
ies but we undertook subgroup analyses to evaluate the impact
of the use of different antibiotics in the treatment of non-severe
pneumonia. Subgroup analyses also showed that a short course
versus a long course of either oral amoxicillin or cotrimoxazole was
equally effective in terms of clinical cure, treatment failure and
relapse rates.
Overall completeness and applicability of
evidence
These findings are very important but they should be interpreted
with caution as they are limited by the small number of studies
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available on the topic. Although only four studies were included
in this analyses, all included studies had a good number of partic-
ipants contributing to its results. The impact of a short duration
of antibiotic therapy on other secondary outcomes, that is, mor-
tality at one month and additional interventions used, could not
be assessed in this review due to the non-availability of data.
Quality of the evidence
The World Health Organization (WHO) definition of CAP fo-
cuses on the clinical findings and respiratory cut-offs. This simpli-
fied syndromic diagnosis of childhood CAP poses a challenge in
the accurate diagnosis of CAP cases as shown by a study conducted
in Pakistan. This study (Hazir 2006) showed that only 14% of
children diagnosed with pneumonia by theWHO criteria had ra-
diological evidence of pneumonia. These findings have also been
supported by other community-based studies in Pakistan (Nizami
2005). This raises concerns as to the robustness of the clinical cri-
teria being used for pneumonia diagnosis. Also, once diagnosed
with non-severe CAP, children are treated with oral cotrimoxazole
or amoxicillin and are followed up at home after 48 hours. Identi-
fication of the true cause (bacterial or viral) of CAP is limited and
in such a scenario treatment of a non-bacterial CAP with inexpen-
sive antibacterial agents therefore significantly increases the risk of
development of antimicrobial resistance. This poses a significant
public health problem and needs attention in the form of modifi-
cation of clinical diagnostic criteria and management guidelines.
Potential biases in the review process
We undertook a systematic, thorough search of the literature to
identify all studies meeting the inclusion criteria for this review
and we are confident that all trials meeting the inclusion criteria
are included in this review. We independently and in duplicate
selected studies and extracted data and we reached consensus by
discussing any discrepancies. A protocol was published for this
review.
Agreements and disagreements with other
studies or reviews
We found no significant differences between three and five days
of the same antibiotics for non-severe pneumonia. A recent study
from India (Awasthi 2008) compared three days of oral amoxicillin
with placebo in 1671 children aged 2 to 59 months with non-
severe pneumonia who also had a wheeze. The investigators of
this trial used WHO criteria and found that placebo treatment
was associated with clinical failure (odds ratio (OR) 1.28; 95% CI
1.01 to 1.62) and they concluded that three days of oral antibiotics
should be the current treatment standard for patients with non-
severe pneumonia in low-income countries.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence provided in this review suggests that a short-course (three
days) of antibiotic therapy is equally as effective as a longer treat-
ment (five days) for non-severe CAP in children under five years
of age. No difference was found in terms of clinical cure rates at
the end of treatment, rates of treatment failure or relapse rates
within seven days of clinical cure, with the different durations of
antibiotic therapy. Therefore a shorter course of antibiotic therapy
should benefit both the individual, family and the public.
Implications for research
This review only allowed a comparison of three days of treatment
against five days. More well designed randomised controlled trials
comparing different durations of short and long courses of antibi-
otic therapies are needed to support our review findings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agarwal 2004
Methods Double-blind, placebo-controlled, randomised trial. Block randomisation was done with
variable block sizes. The allocation concealment was adequate. For both treatment
groups, tablets were placed in serially numbered opaque white envelopes, each of which
contained a green envelope containing 11 doses of amoxicillin for 3 days and a blue
envelope containing 8 doses of either amoxicillin or placebo for the next 2 days. Blinding
of participants, caregiver and outcome assessor was done adequately. The loss to follow
up was 5.4% by day 5, and 6.8% by day 14
Participants Children aged 2 to 59 months with cough, rapid respiration, or difficulty in breathing.
Non-severe CAP was defined as respiratory rate of more than or equal to 50 breaths per
minute for children aged 2 to 11 months, or more than or equal to 40 breaths per minute
for children aged 12 to 59 months
Children having signs of severe CAP or disease (cyanosis, convulsions, inability to drink,
difficulty waking, severe malnutrition, stridor), other conditions requiring antibiotic
treatment, clinically recognised congenital heart disease, chronic systemic disorders, a
history of repeated wheezing or asthma, who had been hospitalised in the previous 2
weeks, taken antibiotics in the previous 2 days, had measles within the previous month,
or a history of penicillin allergy were excluded. Patients with fever or wheeze received
symptomatic treatment before enrolment
Those whose fast-breathing persisted were enrolled after their parents or guardian had
consented
There were no substantial differences in the baseline characteristics of the treatment
groups. In all, 2188 patients were recruited, 1095 in the 3 days of amoxicillin treatment
group and 1093 in the 5 days of treatment group
Interventions All participants received scored dispersible tablets of amoxicillin (125 mg) for the first 3
days. Amoxicillin was given 3 times daily dissolved in 5 ml of water. Effective dose per
kilogram body weight varied from 31 to 54 mg/day. For the next 2 days participants
received either amoxicillin or placebo
There were 1095 subjects in the 3 days of amoxicillin treatment group and 1093 in the
5 days of treatment group
Outcomes Primary outcome: proportions of children recovering after 3 days and 5 days of treatment
Secondary outcomes: treatment failure defined as development of chest in-drawing,
convulsions, drowsiness or inability to drink at any time; respiratory rate above age-
specific cut-off points on day 3 or later; or oxygen saturation by pulse oximetry < 90%
on day 3; proportions relapsed within the next 6 to 14 days, proportions with resistant
strains of S. pneumoniae or H. influenzae in nasopharyngeal cultures at enrolment and
at 14-day follow up, direct medical costs of treating clinical failures and relapses, and
proportion of participants with nasopharyngeal aspirates positive for respiratory syncytial
virus at enrolment
Notes Study was conducted in the outpatient departments of 7 referral hospitals in India
Risk of bias
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Agarwal 2004 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomised; Block randomisa-
tion, with variable sized blocks, was done
for each participating site to avoid unblind-
ing.”
Comment: adequately done
Allocation concealment? Low risk Quote: “For both treatment groups, tablets
were placed in serially numbered opaque
white envelopes, each of which contained
a green envelope containing 11 doses of
amoxicillin for three days and a blue enve-
lope containing eight doses of either amox-
icillin or placebo for the next two days.”
Comment: adequately done
Blinding?
All outcomes
Unclear risk Quote: “Double blind”
Incomplete outcome data addressed?
All outcomes
Low risk Loss to follow up was 5.4% by day 5, and
6.8% by day 14
Free of selective reporting? Low risk Study appears to be free from other bias
Free of other bias? Low risk Study appears to be free from other bias
Kartasasmita 2002
Methods Double-blind, randomised, placebo-controlled, multi-centre equivalence trial. Trial was
carried out in 2 sites in Indonesia and Bangladesh
Participants Children aged 2 to 59 months with non-severe CAP
Interventions Participants received oral cotrimoxazole either for 3 days or for 5 days. There were 1008
children in the 3 days cotrimoxazole group and 1014 in the 5 days group. Effective dose
per kilogram body weight varied from 30 to 45 mg/kg/day
Outcomes Clinical cure, treatment failure, relapse rates and effect on antimicrobial resistance in
nasopharyngeal S. pneumoniae and H. influenzae isolates
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Kartasasmita 2002 (Continued)
Adequate sequence generation? Unclear risk Quote: “Randomised”
Comment: insufficient information to per-
mit judgement
Allocation concealment? Unclear risk Insufficient information to permit judge-
ment
Blinding?
All outcomes
Unclear risk Quote: “double-blind”
Comment: insufficient information to per-
mit judgement
Incomplete outcome data addressed?
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Free of selective reporting? Unclear risk Insufficient information to permit judge-
ment
Free of other bias? Unclear risk Insufficient information to permit judge-
ment
Lupison 1999
Methods The study was conducted fromDecember 1991 to December 1992 in Pasay City, Metro
Manila, Philippines where the ARI case management strategy was implemented as part
of a feasibility study of ARI control programme implementation
Participants Children of 2 to 59 months (with cough and fast breathing) were recruited and enrolled
in the outpatient section of Pasay City General Hospital. Participants were assessed and
recruited consecutively from 5 health centres in the catchment area by trained nurses
and referred to the project physician based at the hospital outpatient section for final
assessment and enrolment
Interventions Antibiotic treatment was supervised for the initial dose by the hospital project nurse
and the subsequent doses in the respective homes by the field nurses for Days 1 to 3.
Children > 12 month old were given cotrimoxazole 80 mg BID and children 2 to 12
months old were given cotrimoxazole 40 mg BID
Outcomes Relapse and re-infection rates after the 3- and the 5-day courses of cotrimoxazole
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “The numbers were computer gen-
erated and known only to the programmer.
”
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Lupison 1999 (Continued)
Comment: adequately done
Allocation concealment? Low risk Quote: “Randomisation was done on Day
4 of treatment for those assessed to have
treatment success by picking out a num-
bered bottle of identical drugs from a box
kept at the hospital and appropriate num-
bers were tagged to the respective patient
charts.”
Comment: adequately done
Blinding?
All outcomes
Low risk Quote: “double-blind”; “nurses were
blinded to treatment regimen for patient”
Comment: adequately done
Incomplete outcome data addressed?
All outcomes
Low risk 5% attrition reported along with their rea-
sons
Free of selective reporting? Low risk Study seems free from any selective bias
Free of other bias? Low risk Study seems to be free from any other bias
MASCOT 2002
Methods Double-blind, randomised, placebo-controlled trial. The randomisation scheme was
generated by a computer programme at WHO, Geneva, with uneven blocks of 4, 6 and
8. The allocation concealment was adequate. Participant, caregiver and the outcome
assessor were blinded to the intervention assignment. Loss to follow up was less than 5%
Participants Children aged 2 to 59 months with non-severe CAP. Children were classified using the
standard WHO algorithm for ARI as having non-severe pneumonia-cough or difficulty
breathing with fast breathing (respiratory rate of more than or equal to 50 breaths per
minute for children aged 2 to 11 months, or more than or equal to 40 breaths per minute
for children aged 12 to 59 months)
Excluded children include those who had underlying chronic illness, a history of 3 or
more episodes of wheeze or acute bronchial asthma, and who had used any antibiotic in
appropriate doses during the previous 48 hours. The baseline characteristics were almost
similar and showed that 1051 (54%) of children were younger than 1 year old
Interventions All children received 15 mg/kg oral amoxicillin every 8 hours for 3 days. In the next
2 days, children were given either active medicine or placebo. Oral salbutamol and
paracetamol were given when needed
Outcomes Primary outcome: treatment failure, which included any patient who had the study drug
changed by study staff up to 5 days after enrolment, developed severe pneumonia/disease,
did not improve, or who died
Secondary outcome: relapse of disease defined as development of any sign of pneumonia
between days 6 and 14 after fast breathing had initially returned to normal, clinical
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MASCOT 2002 (Continued)
resolution defined as return of respiratory rate to the normal age-specific range
Notes This study was done in 7 sites in 5 cities of Pakistan (Gilgit, Islamabad, Lahore, Multan
and Rawalpindi)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “randomized; The randomisation
scheme was generated by a computer pro-
gram at WHO, Geneva, with uneven
blocks of four, six, and eight.”
Comment: adequately done
Allocation concealment? Low risk Quote: “Self-adhesive sticking labels with
unique identification numbers were pre-
pared in Geneva. A copy of the randomi-
sation list with unique identification num-
bers was given to a health professional not
associated with the study, who randomized
the study drugs.”
Comment: adequately done
Blinding?
All outcomes
Low risk Quote: “double-blind; drug assignment
was concealed from patients, parents, and
study personnel.”
Incomplete outcome data addressed?
All outcomes
Low risk 2% excluded from intervention group and
3% from control arm. Their reason for ex-
clusions were described in the text and flow
diagram
Free of selective reporting? Low risk Study seems to be free from selective bias
Free of other bias? Low risk Study appears to be free from other bias
CAP: community-acquired pneumonia
ARI: acute respiratory infection
BID: twice daily
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
El Moussaoui 2006 Age of participants was > 18 years
Ficnar 1997 Age of participants 6 months to 12 years; outcomes of interest in population of 6 to 59 months of age children
are not separately reported; quasi-randomised trial
Harris 1998 Age of participants was 6 months to 16 years
Leophonte 2002 Age of participants was > 18 years
Peltola 2001 Age of participants was 3 months to 15 years; outcomes of interest in population of 6 to 59 months of age
children are not separately reported
Siegal 1999 Age of participants was > 18 years
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D A T A A N D A N A L Y S E S
Comparison 1. 3 days versus 5 days treatment with the same antibiotic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical cure 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 All 3 5763 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.97, 1.01]
1.2 3 versus 5 days amoxicillin
therapy
2 4012 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.97, 1.01]
1.3 3 versus 5 days
cotrimoxazole therapy
1 1751 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.97, 1.03]
2 Treatment failure 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 All 3 5763 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.92, 1.25]
2.2 3 versus 5 days amoxicillin
therapy
2 4012 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.94, 1.33]
2.3 3 versus 5 days
cotrimoxazole therapy
1 1751 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.72, 1.30]
3 Relapse rate 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 All 4 5469 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.84, 1.42]
3.2 3 versus 5 days amoxicillin
therapy
2 3577 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.69, 1.60]
3.3 3 versus 5 days
cotrimoxazole therapy
2 1892 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.80, 1.58]
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Analysis 1.1. Comparison 1 3 days versus 5 days treatment with the same antibiotic, Outcome 1 Clinical
cure.
Review: Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months
Comparison: 1 3 days versus 5 days treatment with the same antibiotic
Outcome: 1 Clinical cure
Study or subgroup 3 days treatment 5 days treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All
Agarwal 2004 980/1033 983/1026 38.0 % 0.99 [ 0.97, 1.01 ]
Kartasasmita 2002 799/879 790/872 30.6 % 1.00 [ 0.97, 1.03 ]
MASCOT 2002 803/980 811/973 31.4 % 0.98 [ 0.94, 1.02 ]
Subtotal (95% CI) 2892 2871 100.0 % 0.99 [ 0.97, 1.01 ]
Total events: 2582 (3 days treatment), 2584 (5 days treatment)
Heterogeneity: Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
2 3 versus 5 days amoxicillin therapy
Agarwal 2004 980/1033 983/1026 54.8 % 0.99 [ 0.97, 1.01 ]
MASCOT 2002 803/980 811/973 45.2 % 0.98 [ 0.94, 1.02 ]
Subtotal (95% CI) 2013 1999 100.0 % 0.99 [ 0.97, 1.01 ]
Total events: 1783 (3 days treatment), 1794 (5 days treatment)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
3 3 versus 5 days cotrimoxazole therapy
Kartasasmita 2002 799/879 790/872 100.0 % 1.00 [ 0.97, 1.03 ]
Subtotal (95% CI) 879 872 100.0 % 1.00 [ 0.97, 1.03 ]
Total events: 799 (3 days treatment), 790 (5 days treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
0.2 0.5 1 2 5
Short course treatment Long course treatment
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Analysis 1.2. Comparison 1 3 days versus 5 days treatment with the same antibiotic, Outcome 2 Treatment
failure.
Review: Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months
Comparison: 1 3 days versus 5 days treatment with the same antibiotic
Outcome: 2 Treatment failure
Study or subgroup 3 days treatment 5 days treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All
Agarwal 2004 53/1033 43/1026 15.0 % 1.22 [ 0.83, 1.81 ]
Kartasasmita 2002 80/879 82/872 28.6 % 0.97 [ 0.72, 1.30 ]
MASCOT 2002 177/980 162/973 56.4 % 1.08 [ 0.89, 1.32 ]
Subtotal (95% CI) 2892 2871 100.0 % 1.07 [ 0.92, 1.25 ]
Total events: 310 (3 days treatment), 287 (5 days treatment)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
2 3 versus 5 days amoxicillin therapy
Agarwal 2004 53/1033 43/1026 21.0 % 1.22 [ 0.83, 1.81 ]
MASCOT 2002 177/980 162/973 79.0 % 1.08 [ 0.89, 1.32 ]
Subtotal (95% CI) 2013 1999 100.0 % 1.11 [ 0.94, 1.33 ]
Total events: 230 (3 days treatment), 205 (5 days treatment)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
3 3 versus 5 days cotrimoxazole therapy
Kartasasmita 2002 80/879 82/872 100.0 % 0.97 [ 0.72, 1.30 ]
Subtotal (95% CI) 879 872 100.0 % 0.97 [ 0.72, 1.30 ]
Total events: 80 (3 days treatment), 82 (5 days treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
0.2 0.5 1 2 5
Short course treatment Long course treatment
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Analysis 1.3. Comparison 1 3 days versus 5 days treatment with the same antibiotic, Outcome 3 Relapse
rate.
Review: Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months
Comparison: 1 3 days versus 5 days treatment with the same antibiotic
Outcome: 3 Relapse rate
Study or subgroup 3 days treatment 5 days treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All
Agarwal 2004 32/980 29/983 28.9 % 1.11 [ 0.67, 1.82 ]
Kartasasmita 2002 62/799 55/790 55.2 % 1.11 [ 0.79, 1.58 ]
Lupison 1999 4/153 3/150 3.0 % 1.31 [ 0.30, 5.74 ]
MASCOT 2002 12/803 13/811 12.9 % 0.93 [ 0.43, 2.03 ]
Subtotal (95% CI) 2735 2734 100.0 % 1.09 [ 0.84, 1.42 ]
Total events: 110 (3 days treatment), 100 (5 days treatment)
Heterogeneity: Chi2 = 0.23, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
2 3 versus 5 days amoxicillin therapy
Agarwal 2004 32/980 29/983 69.1 % 1.11 [ 0.67, 1.82 ]
MASCOT 2002 12/803 13/811 30.9 % 0.93 [ 0.43, 2.03 ]
Subtotal (95% CI) 1783 1794 100.0 % 1.05 [ 0.69, 1.60 ]
Total events: 44 (3 days treatment), 42 (5 days treatment)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
3 3 versus 5 days cotrimoxazole therapy
Kartasasmita 2002 62/799 55/790 94.8 % 1.11 [ 0.79, 1.58 ]
Lupison 1999 4/153 3/150 5.2 % 1.31 [ 0.30, 5.74 ]
Subtotal (95% CI) 952 940 100.0 % 1.12 [ 0.80, 1.58 ]
Total events: 66 (3 days treatment), 58 (5 days treatment)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
0.2 0.5 1 2 5
Short course treatment Long course treatment
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A P P E N D I C E S
Appendix 1. Previous search
We searched The Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects
(DARE) (The Cochrane Library 2007, Issue 3); MEDLINE (OVID) (January 1966 to September 2007); EMBASE (Embase.com)
(1974 to September 2007); and LILACS (1982 to September 2007).
The following search terms were combined with the highly sensitive search strategy devised by Dickersin et al (Dickersin 1994) and
run in MEDLINE and CENTRAL. The terms were adapted to search EMBASE and LILACS.
MEDLINE (OVID)
1 exp Pneumonia/
2 exp Community-Acquired Infections/
3 and/1-2
4 (pneumonia or CAP).mp.
5 lower respiratory tract infection$.mp.
6 lower respiratory infection$.mp.
7 LRTI.mp.
8 or/3-7
9 exp Anti-Bacterial Agents/
10 antibiotic$.mp.
11 exp Anti-Infective Agents/
12 exp Amoxicillin/
13 exp Penicillins/
14 exp Ampicillin/
15 exp Trimethoprim-Sulfamethoxazole Combination/
16 exp Macrolides/
17 exp Erythromycin/
18 exp Azithromycin/
19 exp Clarithromycin/
20 (penicillin$ or amoxicillin or ampicillin or cotrimoxazole or macrolide$ or erythromycin or azithromycin or clarithromycin).mp.
21 or/9-20
22 exp Child/
23 (child or children).mp.
24 exp Infant/
25 (infant or infants).mp.
26 (pediatric or pediatric).mp.
27 or/22-26
28 8 and 21 and 27
We limited searches to human studies and there were no language or publication restrictions. We also searched the related conference
proceedings for relevant abstracts.We contacted organisations and researchers in the field and pharmaceutical companies for information
on unpublished and ongoing trials. We also checked the reference lists of all trials identified by the above methods.
Appendix 2. Embase.com search strategy
19. #15 AND #18
18. #16 OR #17
17. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR assign*:
ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti
16. ’randomized controlled trial’/exp OR ’double blind procedure’/exp OR ’single blind procedure’/exp OR ’crossover procedure’/exp
15. #5 AND #11 AND #14
14. #12 OR #13
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13. infant*:ab,ti OR infancy:ab,ti OR baby*:ab,ti OR babies:ab,ti OR child*:ab,ti OR schoolchild*:ab,ti OR (school NEAR/2 (age*
OR nursery OR primary OR elementary)):ab,ti OR preschool*:ab,ti OR kid:ab,ti OR kids:ab,ti OR toddler*:ab,ti OR boy*:ab,ti OR
girl*:ab,ti OR pediatric*:ab,ti OR pediatric*:ab,ti
12. ’child’/exp OR ’pediatrics’/exp OR ’nursery school’/exp OR ’kindergarten’/exp OR ’primary school’/exp
11. #6 OR #7 OR #8 OR #9 OR #10
10. penicillin*:ab,ti OR amoxicillin*:ab,ti OR ampicillin*:ab,ti OR cotrimoxazole*:ab,ti OR macrolide*:ab,ti OR erythromycin*:ab,ti
OR azithromycin*:ab,ti OR clarithromycin*:ab,ti OR ’trimethoprim-sulfamethoxazole’:ab,ti
9. ’cotrimoxazole’/exp
8. ’antiinfective agent’/de
7. antibiotic*:ab,ti
6. ’antibiotic agent’/exp
5. #1 OR #2 OR #3 OR #4
4. ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR ’lower respiratory infection’:ab,ti OR ’lower
respiratory infections’:ab,ti OR lrti:ab,ti
3. ’lower respiratory tract infection’/de
2. pneumon*:ab,ti OR cap:ab,ti
1. ’pneumonia’/exp
Appendix 3. LILACS search strategy
“PNEUMONIA” or “aspiration PNEUMONIA” or “bronchiolitis obliterans organizing PNEUMONIA” or “cryptogenic organiz-
ing PNEUMONIA” or “eosinophilic PNEUMONIA” or “lobar PNEUMONIA” or “mycoplasma PNEUMONIA” or “pneumocystis
PNEUMONIA” or “staphylococcal PNEUMONIA” or “ventilator-associated PNEUMONIA” or “atypical interstitial PNEUMONIA
of cattle” or “enzootic PNEUMONIA of swine” or “mycoplasmal PNEUMONIA of swine” or “PNEUMONIA of swine, enzootic”
or “PNEUMONIA of swine, mycoplasmal” or “PNEUMONIA, aspiration” or “PNEUMONIA, atypical interstitial, of cattle” or
“PNEUMONIA, bacterial” or “PNEUMONIA, eosinophilic” or “PNEUMONIA, interstitial” or “PNEUMONIA, interstitial plasma
cell” or “PNEUMONIA, lipid” or “PNEUMONIA, lobar” or “PNEUMONIA, mycoplasma” or “PNEUMONIA, pneumococcal” or
“PNEUMONIA, pneumocystis” or “PNEUMONIA, primary atypical” or “PNEUMONIA, radiation” or “PNEUMONIA, staphy-
lococcal” or “PNEUMONIA, ventilator-associated” or “PNEUMONIA, viral” or “chlamydia PNEUMONIAe” or “chlamydophila
PNEUMONIAe” or “diplococcus PNEUMONIAe” or “klebsiella PNEUMONIAe” or “meningitis, streptococcus PNEUMONIAe”
or “mycoplasma PNEUMONIAe” or “streptococcus PNEUMONIAe” or “streptococcus PNEUMONIAe infections” [Subject descrip-
tor] and ( ( ( ( ( ( ( ( “ANTIBIOTICS” or “ANTIBIOTICS, penicillin” ) or “AMOXICILLIN” ) or “PENICILLIN g” ) or “AMPI-
CILLIN” ) or “TRIMETHOPRIM-SULFAMETHOXAZOLE combination” ) or “MACROLIDES” ) or “ERYTHROMYCIN” )
or “AZITHROMYCIN” ) or “CLARITHROMYCIN” [Subject descriptor] and ( ( “CHILD” ) or “INFANT” ) or “PEDIATRICs”
[Subject descriptor]
pneumon$ [Words] and antibiotic$ or penicillin$ or amoxicillin$ or ampicillin$ or macrolide$ or erythromycin$ or azithromycin$ or
clarithromycin$ or cotrimoxazole$ [Words] and child$ or infan$ or preschool$ or toddler$ or paediatr$ or pediatr$ [Words]
WH A T ’ S N E W
Last assessed as up-to-date: 1 September 2010.
Date Event Description
2 September 2010 New search has been performed This is an update of our last version which was published in 2008. One new
study was found and included in this review. Overall, the conclusions remain
unchanged
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H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 2, 2008
Date Event Description
19 December 2007 Amended Converted to new review format.
5 September 2007 New search has been performed Searches conducted.
C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by Dr Batool Azra Haider (BAH) under the guidance of Dr Zulfiqar A Bhutta (ZAB). Data extraction was
done by BAH and Zohra S Lassi (ZSL). BAH and ZSL entered the data, created the comparisons, carried out the analysis and wrote
the text of the review. ZAB provided support and guidance for the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Aga Khan University, Pakistan.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗administration & dosage]; Community-Acquired Infections [drug therapy]; Drug Administration Schedule;
Pneumonia [∗drug therapy]; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome
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MeSH check words
Child, Preschool; Humans; Infant
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